The increasing use of oral glucagon-like peptide-1 (GLP-1) agonists, a class of drugs initially developed for diabetes management and now widely prescribed for weight loss, hinges on a compound that may carry its own risks. Researchers at the University of Adelaide in Australia are highlighting potential adverse effects associated with sodium salcaprozate (SNAC), a key ingredient used to enhance the oral bioavailability of these medications, including oral semaglutide. Without SNAC, the oral form of semaglutide would be ineffective, as the drug is degraded in the stomach.
The growing obesity epidemic is driving demand for these medications, with a clear preference for oral administration over injections. This shift underscores the critical need to fully understand the potential downsides of SNAC, which acts as an “enhancer” allowing the drug to be absorbed into the bloodstream. The focus on oral GLP-1 agonists and their reliance on SNAC makes a thorough investigation of potential side effects all the more urgent.
How SNAC Works and Why It’s Needed
GLP-1 agonists mimic a natural hormone that regulates appetite and blood sugar. While effective when injected, these large molecule drugs are typically broken down in the digestive system, rendering them useless if taken orally. SNAC overcomes this challenge by temporarily increasing permeability in the intestinal lining, allowing the GLP-1 agonist to be absorbed. According to research published in ScienceDirect, SNAC has gained attention due to its success in clinical trials of oral semaglutide [1].
Still, the mechanism isn’t simply about opening pathways for the drug. Recent research suggests SNAC similarly elevates pH levels in the stomach, induces changes in the drug’s structure, and inhibits pepsin, an enzyme involved in protein digestion. This multi-faceted action is crucial for protecting the semaglutide from degradation, but it also raises questions about potential unintended consequences.
Conflicting Mechanisms and Limited Efficacy
For decades, SNAC was believed to increase passive transcellular permeation – essentially making the intestinal lining more porous – through increased lipophilicity. However, University College Dublin researchers found equivocal evidence for discrete mechanisms at the level of epithelial interactions in the small intestine, particularly at the high doses used in clinical settings [2]. The study, published in 2019, also noted that sodium caprate (C10) – another intestinal permeation enhancer – acts by opening tight junctions and perturbing cell membranes.
The research suggests that neither SNAC nor C10 consistently delivers substantial improvements in oral bioavailability. Human trials have shown single-digit, highly variable increases in drug absorption when using these permeation enhancers. While this may be sufficient for potent drugs like GLP-1 agonists, the variability and potential for side effects warrant further scrutiny.
Safety Profile and Regulatory Status
SNAC currently has a generally regarded as safe (GRAS) status and is approved by the Food and Drug Administration (FDA) as a medical food, specifically in the formulation Eligen®-Vitamin B12, manufactured by Emisphere in Roseland, NJ [2]. Sodium caprate, has a long history of use in humans and is approved as a food additive. Despite these approvals, the long-term effects of repeated SNAC exposure, particularly in the context of widespread GLP-1 agonist use, remain largely unknown.
Researchers are particularly interested in understanding how SNAC’s impact on stomach pH and pepsin activity might affect digestion and nutrient absorption over time. The potential for altered gut microbiome composition is another area of concern that requires further investigation.
The Importance of Ongoing Research
The crystallographic information of SNAC and its free acid form, salcaprozoic acid, is also being studied to better understand its properties and behavior within the body [3]. This detailed characterization could provide insights into its mechanism of action and potential for interactions with other medications or dietary components.
As oral GLP-1 agonists become increasingly prevalent in the treatment of obesity and related metabolic disorders, a comprehensive understanding of SNAC’s effects is paramount. Ongoing research is essential to identify potential risks, optimize dosing strategies, and ensure the safe and effective use of these medications.
The University of Adelaide team’s work serves as a crucial reminder that even well-established drug delivery systems require continuous evaluation. The benefits of oral GLP-1 agonists are significant, but they must be weighed against the potential, and currently incompletely understood, consequences of relying on enhancers like SNAC.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share this article with anyone considering or currently using oral GLP-1 agonists, and join the conversation in the comments below.
